[HTML][HTML] HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management

M Lechner, J Liu, L Masterson, TR Fenton - Nature reviews Clinical …, 2022 - nature.com
Abstract Human papillomavirus (HPV)-positive (HPV+) oropharyngeal squamous cell
carcinoma (OPSCC) has one of the most rapidly increasing incidences of any cancer in high …

Head and neck cancer

MD Mody, JW Rocco, SS Yom, RI Haddad, NF Saba - The Lancet, 2021 - thelancet.com
Head and neck cancer is the seventh most common type of cancer worldwide and comprise
of a diverse group of tumours affecting the upper aerodigestive tract. Although many different …

NCCN Guidelines® insights: Head and neck cancers, version 1.2022: Featured updates to the NCCN guidelines

JJ Caudell, ML Gillison, E Maghami, S Spencer… - Journal of the National …, 2022 - jnccn.org
The NCCN Guidelines for Head and Neck Cancers address tumors arising in the oral cavity
(including mucosal lip), pharynx, larynx, and paranasal sinuses. Occult primary cancer …

[HTML][HTML] Head and neck squamous cell carcinoma

DE Johnson, B Burtness, CR Leemans… - Nature reviews Disease …, 2020 - nature.com
Most head and neck cancers are derived from the mucosal epithelium in the oral cavity,
pharynx and larynx and are known collectively as head and neck squamous cell carcinoma …

Phase II randomized trial of transoral surgery and low-dose intensity modulated radiation therapy in resectable p16+ locally advanced oropharynx cancer: an ECOG …

RL Ferris, Y Flamand, GS Weinstein, S Li… - Journal of clinical …, 2022 - ascopubs.org
PURPOSE Definitive or postoperative chemoradiation (CRT) is curative for human
papillomavirus–associated (HPV+) oropharynx cancer (OPC) but induces significant toxicity …

Reduced-dose radiation therapy for HPV-associated oropharyngeal carcinoma (NRG Oncology HN002)

SS Yom, P Torres-Saavedra, JJ Caudell… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE Reducing radiation treatment dose could improve the quality of life (QOL) of
patients with good-risk human papillomavirus–associated oropharyngeal squamous cell …

Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non …

ML Gillison, AM Trotti, J Harris, A Eisbruch, PM Harari… - The Lancet, 2019 - thelancet.com
Background Patients with human papillomavirus (HPV)-positive oropharyngeal squamous
cell carcinoma have high survival when treated with radiotherapy plus cisplatin. Whether …

The changing therapeutic landscape of head and neck cancer

JD Cramer, B Burtness, QT Le, RL Ferris - Nature reviews Clinical …, 2019 - nature.com
Head and neck cancers are a heterogeneous collection of malignancies of the upper
aerodigestive tract, salivary glands and thyroid. In this Review, we primarily focus on the …

Head and neck cancer

LQM Chow - New England Journal of Medicine, 2020 - Mass Medical Soc
Head and Neck Cancer Most head and neck cancers (73% in the United States) are now
related to human papillomavirus infection rather than tobacco and alcohol. Primary cancers …

Treating head and neck cancer in the age of immunotherapy: a 2023 update

A Bhatia, B Burtness - Drugs, 2023 - Springer
Most patients diagnosed with head and neck squamous cell carcinoma (HNSCC) will
present with locally advanced disease, requiring multimodality therapy. While this approach …